NTX-083

NTX-083 is an investigational **small-molecule** therapeutic being developed by Neusignal Therapeutics for **Alzheimer's disease**. Public disclosures describe it as a **K-ATP channel inhibitor**, and third-party drug intelligence sources also describe it as an **ATP1A3 inhibitor**. The program has entered **Phase 1** development: an investigator-initiated first-in-human single-dose study in healthy volunteers at the University of Tokyo Hospital evaluated safety, tolerability, and pharmacokinetics, and a company-sponsored multiple ascending dose Phase 1 study in healthy subjects was subsequently registered. Neusignal has also indicated plans to use these data to support a future Phase 1b study in patients with Alzheimer's disease in the United States.